Geoffrey Ku, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy drugs and the search for biomarkers that will help identify patients more likely to respond, not only to these medications, but to combinations of immunotherapies, other targeted treatments, chemotherapy drugs, and radiation.
http://www.ascopost.com/videos/2017-gastrointestinal-cancers-symposium/geoffrey-ku-md-mba-on-gastric-and-esophageal-cancers-expert-perspectives-on-immunotherapy/
Geoffrey Ku, MD, MBA, on Gastric and Esophageal Cancers: Expert Perspectives on Immunotherapy